United States · FDA National Drug Code directory
Lifyorli
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 76346-550_41bf3142-d0f6-4f0c-b6da-5abe8ad3db43
- Product NDC
- 76346-550
- Form
- KIT
- Composition / generic term
- Relacorilant
- Labeler
- Corcept Therapeutics Incorporated
- Marketing category
- NDA
- Marketing start / end (source format)
- 20260325
- Source listing expiry
- 20271231
Source-listed ingredients
Separate ingredient quantities are not available in this snapshot. Any composition term above is preserved as source text.
These values do not establish equivalence or a dose recommendation.
Packages
- 1 BLISTER PACK in 1 CARTON (76346-550-03) / 1 KIT in 1 BLISTER PACK (76346-550-33) * 1 CAPSULE in 1 PACKAGE, COMBINATION (76346-025-01) * 1 CAPSULE in 1 PACKAGE, COMBINATION (76346-100-01) · 76346-550-03
- 3 CARTON in 1 CARTON (76346-550-09) / 1 BLISTER PACK in 1 CARTON (76346-550-03) / 1 KIT in 1 BLISTER PACK (76346-550-33) * 1 CAPSULE in 1 PACKAGE, COMBINATION (76346-025-01) * 1 CAPSULE in 1 PACKAGE, COMBINATION (76346-100-01) · 76346-550-09
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →